- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CP-88059 | CP-88059-27 | CP-880591 | CP-8805927 | Geodon®
ziprasidone is an approved drug (FDA (2001))
Compound class: Synthetic organic
Comment: Ziprasidone is a monoaminergic antagonist with affinity for a range of receptors including dopamine receptors, alpha 1 and 2 adrenoceptors, the histamine H1 receptor, and serotonin 5-HT receptors. Marketed formulations may contain ziprasidone hydrochloride (PubChem CID 219099).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: ziprasidone
|No information available.
|Summary of Clinical Use
|Used in the treatment of schizophrenia and related psychotic disorders. Additionally used as a monotherapy for the acute treatment of bipolar manic or mixed episodes and as an adjunct to lithium or valproate for maintenance treatment of bipolar disorder.
|Mechanism Of Action and Pharmacodynamic Effects
|The antipsychotic effects of ziprasidone are believed to be due to its antagonism of D2 receptors in the mesolimbic pathways and 5HT2A receptors in the frontal cortex.
For extended ADME data see the following: